patritumab
daiichi sankyo
['patritumab']
 poster at #asco22 shows efficacy of patritumab in patients without classical egfr mutations 
Medical Oncologist at Memorial Sloan Kettering. Clinical focus on patients with lung & thymic cancers. COI: https://t.co/lXxGGb6HFw